Prelude Therapeutics Incorporated (PRLD)

3.8600 -0.1300 (-3.26%) At close: 04:00PM EDT

Prelude Therapeutics Incorporated

175 Innovation Boulevard
Wilmington, DE 19805
United States
302 467 1280
https://preludetx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 128

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Krishna Vaddi D.V.M., Ph.D.	Founder, CEO & Director	905.92k	N/A	1966
Dr. Edna Huang M.D.	President & Chief Medical Officer	865.63k	N/A	1973
Lindsey Trickett	Vice President of Investor Relations	N/A	N/A	N/A
Ms. Michele Porreca M.B.A.	Chief People Officer	N/A	N/A	N/A
Dr. Andrew P. Combs Ph.D.	Executive VP & Chief Chemistry Officer	562.46k	N/A	1967
Mr. Naveen Babbar Ph.D.	Senior Vice President of Translation Medicine	N/A	N/A	N/A
Dr. William B. Novotny M.D.	Senior Vice President of Clinical Development	N/A	N/A	N/A
Dr. Wan-Jen Hong M.D.	Senior Vice President of Clinical Development	N/A	N/A	1979

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Corporate governance

Prelude Therapeutics Incorporated’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.